Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, ann...
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentatio...
HC Wainwright & Co. analyst Oren Livnat maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and raises the price t...
Craig-Hallum analyst Chase Knickerbocker maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and raises the price targ...
Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $22 price target.
Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $22 price target.
Cash, cash equivalents and marketable securities were $88.8 million as of March 31, 2024.
Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate...
Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $22 price target.
